Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Parker-Hannifin (PH) upgraded to Buy from Neutral at BofA/Merrill, with analyst Andrew Obin saying he sees significant earnings upside in the coming years from cyclical upside from an industrial recovery combined with the operating turnaround story and integration of Clarcor. 2. Nordson (NDSN) upgraded to Overweight from Sector Weight at KeyBanc, with analyst Jeffrey Hammond saying that despite concerns, he believes Nordson's Advanced Technology story has legs given improving semiconductor capex in 2017, meaningful business wins with Chinese smartphone makers pushing for greater automation, and diversification through on-wafer dispense and inspection systems as well as in Medical and Industrial. 3. Acorda Therapeutics (ACOR) upgraded to Neutral from Sell at Goldman, with analyst Salveen Richter saying recent positive data for CVT-301 in Parkinson's removes a worst-case scenario with a potential 2018 market entry to offset Ampyra. 4. On Assignment (ASGN) upgraded to Outperform from Market Perform at Avondale, with analyst Randle Reece saying he expects IT staffing to to lead the U.S. staffing industry in 2017-18 growth, driven by agency staffing demand in large vertical markets such as technology and financial services, and emerging drivers. 5. Brady (BRC) upgraded to Buy from Neutral at Northcoast by analyst Keith Housum, who says he is confident guidance and consensus estimates will move higher given improving operations resulting in lower SG&A, improving revenue expectations and a strengthening balance sheet resulting in lower interest expense. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here